NCT07062354 2026-04-09
CAPT-HN
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
Clinical Trials
16 trialsNCT07517419 2026-04-08
PIPAC in Gastric Peritoneal Metastasis
Chinese University of Hong Kong
Phase 2 Enrolling by invitation
NCT07517510 2026-04-08
HVA-MPAL
Guangdong Second Provincial General Hospital
Phase 2 Enrolling by invitation
NCT07488572 2026-03-23
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
Sun Yat-sen University
Phase 2 Enrolling by invitation
NCT06650748 2026-03-17
NeoMARS
Peking University
Phase 2 Enrolling by invitation
NCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
NCT07441369 2026-03-02
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Fudan University
Phase 2 Enrolling by invitation
NCT05441475 2026-02-25
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Abbisko Therapeutics Co, Ltd
Phase 2 Enrolling by invitation
NCT06250777 2026-02-09
ELPIS
Yonsei University
Phase 2 Enrolling by invitation
NCT06648785 2026-02-05
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies
University of Vermont Medical Center
Phase 2 Enrolling by invitation
NCT07386704 2026-02-04
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
Phase 2 Enrolling by invitation
NCT07376629 2026-01-29
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Huabo Biopharm Co., Ltd.
Phase 2 Enrolling by invitation
NCT06370416 2026-01-28
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Henan Cancer Hospital
Phase 2 Enrolling by invitation
NCT07363031 2026-01-23
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
Phase 2 Enrolling by invitation
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT03181867 2026-01-21
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Enrolling by invitation